A Phase 1 Study to Evaluate ERAS-801 in Patients With Recurrent Glioblastoma (THUNDERBBOLT-1)
Status:
Recruiting
Trial end date:
2025-09-30
Target enrollment:
Participant gender:
Summary
- To evaluate the safety and tolerability of escalating doses of ERAS-801 in study
participants with recurrent glioblastoma multiforme (GBM).
- To determine the Maximum Tolerated Dose (MTD) and/or Recommended Dose (RD) of ERAS-801.
- To evaluate the antitumor activity of ERAS-801.
- To evaluate the PK profile of ERAS-801.